Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Emerging Therapies
Emerging Therapies
Elotuzumab, First-in-Class Monoclonal Antibody Immunotherapy, Improves Outcomes in Patients with Multiple Myeloma
Read More
Emerging Therapies
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
Read More
Emerging Therapies
Nivolumab Makes Headwinds into Liver Cancer
Read More
Emerging Therapies
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
Read More
Emerging Therapies
The Hematology Pipeline Is Abundant
Read More
Emerging Therapies
Anti–PD-1 Antibodies for NSCLC and Renal Carcinoma
Read More
Emerging Therapies
Enthusiasm Sky High for Immunotherapy with Anti–PD-1 Agents in Cancer
Read More
Emerging Therapies
2014 Oncology Pipeline Looks Impressive
Read More
Emerging Therapies
Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes
Read More
Emerging Therapies
GLP-1 Agonists May Protect Patients with Diabetes from Heart Failure
Read More
2
3
4
5
6
7
Page 5 of 7
Results 41 - 50 of 67